Unique ID issued by UMIN | UMIN000001440 |
---|---|
Receipt number | R000001749 |
Scientific Title | Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery |
Date of disclosure of the study information | 2008/10/20 |
Last modified on | 2018/03/26 11:08:30 |
Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery
Influence of human atrial natriuretic peptide on renal function during cardiac surgery
Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery
Influence of human atrial natriuretic peptide on renal function during cardiac surgery
Japan |
myocardial infarction, angina, valvular disease, thoracic aortic aneurysm
Cardiovascular surgery |
Others
NO
Acute renal failure occurs after cardiac surgery in 2.4-16% of patients who have normal renal function preoperatively, and the prognosis of such patients is relatively poor with a mortality rate of 1.3-30%. The mortality rate rises to 33-63.7% in patients requiring hemodialysis.
Human atrial natriuretic peptide (hANP) is a hormone that is secreted in response to stretching of the atrial wall. It has a vasodilatory effect, a potent natriuretic effect, suppresses the renin-angiotensin-aldosterone system (RASS), and causes coronary artery dilation, and has thus been used clinically as a new drug for the treatment of cardiac failure.
we conducted the effect of hANP infusion during CPB on postoperative renal function.
Efficacy
Confirmatory
Pragmatic
Phase II
mortality
complication
Incidence of postoperative acute renal failure
maximum value and percent increase of Cr.
pre-op, 0,1,3,7 days after surgery: ANP, renin activity, angiotensin II, aldosterone, blood urea nitrogen (BUN), Cr, sodium (Na), osmotic pressure (Osm),Urinary Na (U-Na), urinary Cr (U-Cr), and osmotic pressure (U-osm) .
pre-op, 0,1,3,7 days after surgery: creatinine clearance Ccr, fractional sodium excretion, free water clearance and renal failure index.
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Placebo
NO
NO
NO
Numbered container method
2
Treatment
Medicine |
Perioperative administration of hANP
Perioperative non-administration of hANP
20 | years-old | <= |
90 | years-old | > |
Male and Female
Patient undergoing cardiac surgery
Patients from whom informed consent was obtained
renal impairment(Cr>1.3mg/dl)
cardiogenic shock
700
1st name | |
Middle name | |
Last name | Akira Sezai |
Nihon University School of Medicine
Department of Cardiovascular Surgery
30-1 Oyaguchi kami-machi, Itabashi-ku, Tokyo, Japan
03-3972-8111
asezai.med@gmail.com
1st name | |
Middle name | |
Last name | Akira Sezai |
Nihon University School of Medicine
Department of Cardiovascular Surgery
30-1 Oyaguchi kami-machi, Itabashi-ku, Tokyo, Japan
03-3972-8111
asezai.med@gmail.com
Nihon University School of Medicine
self funding
Self funding
a grant for the 60th anniversary of the Alumni Association of Nihon University School of Medicine and for the 50th anniversary of the foundation of Nihon University School of Medicine.
NO
2008 | Year | 10 | Month | 20 | Day |
Unpublished
Completed
1997 | Year | 03 | Month | 01 | Day |
1997 | Year | 03 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2008 | Year | 10 | Month | 20 | Day |
2018 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001749